BP medication uptitration

PreclinicalSmall molecule

BP medication uptitration is one of 6 small molecule programs targeting Hyperaldosteronism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperaldosteronismActive, not recruiting

HyperaldosteronismPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hyperaldosteronism

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

2 2

Baxfendy

AstraZeneca

Phase 3

1 3

LCI699

Novartis

Phase 2

1 4

Ga-Pentixafor

NNantes University Hospital

Phase 2

1 5

Aldosterone Antagonist

IImperial College London

Preclinical

1 6

BP medication uptitration

UUniversity of Alabama at Birmingham

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperaldosteronism1 trial

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

Completed·UUniversity of Alabama at Birmingham·N/A·NCT01897727·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BP medication uptitration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BP medication uptitration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BP medication uptitration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alabama at Birmingham

BP medication uptitration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperaldosteronism1 trial

References

Drug Info

Quick Facts

Related News